This study identifies TAZ deficiency as synthetically lethal with BRAF inhibitors in anaplastic thyroid cancer, revealing a mechanism of resistance and a potential therapeutic target.

Molecular Carcinogenesis · Apr 26, 2026Peer-reviewedCancer Biology

Rewiring of RNA methylation by the oncometabolite fumarate in renal cell carcinoma

Christina M. Fitzsimmons, Mariana D. Mandler, Judith C. Lunger, Dalen Chan, Siddhardha S. Maligireddy, Alexandra C Schmiechen, Supuni Thalalla Gamage, Courtney N. Link, Lisa M. Miller Jenkins, King C. Chan, Þorkell Andrésson, Daniel R. Crooks, Jordan L. Meier, William Marston Linehan, Pedro J. Batista

This study investigates how fumarate accumulation affects RNA methylation by targeting specific 2OGDD enzymes in HLRCC cell lines, revealing differential impacts on m6A, m1A, and f5C demethylases.

NAR Cancer · Jan 9, 2024Peer-reviewedMolecular Biology

Structure-guided bifunctional molecules hit a DEUBAD-lacking hRpn13 species upregulated in multiple myeloma

Xiuxiu Lu, Venkata R. Sabbasani, Vasty Osei Amponsa, Christine N. Evans, Julianna C. King, Sergey G. Tarasov, Marzena Dyba, Sudipto Das, King C. Chan, Charles D. Schwieters, Sulbha Choudhari, Caroline Fromont, Yongmei Zhao, Bao Quoc Tran, Xiang Chen, , Kylie J. Walters

The paper identifies a chemical scaffold targeting hRpn13, revealing a DEUBAD-lacking isoform upregulated in multiple myeloma and demonstrating its potential as a therapeutic target.

Nature Communications · Dec 16, 2021Peer-reviewedMolecular Biology